Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means

Robert A. Kroll, Edward Neuwelt

Research output: Contribution to journalArticle

447 Citations (Scopus)

Abstract

OBJECTIVE: This article reviews historical aspects of the blood-brain barrier (BBB) and recent advances in mechanisms to deliver therapeutic agents across the BBB for the treatment of intracerebral tumors and other neurological diseases. METHODS: The development of the osmotic BBB disruption procedure as a clinically useful technique is described. Osmotic BBB disruption is contrasted with alternative methods for opening or bypassing the BBB, including pharmacological modification of the BBB with bradykinin and direct intracerebral infusion. RESULTS: Laboratory studies have played a fundamental role in advancing our understanding of the BBB and delivery of agents to brain. Preclinical animal studies will continue to serve an integral function in our efforts to improve the diagnosis and treatment of a number of neurological disorders. Techniques involving the modification of the BBB and/or blood-tumor barrier to increase delivery of therapeutic agents have been advanced to clinical trials in patients with brain tumors with very favorable results. CONCLUSION: Improving delivery of agents to the brain will play a major role in the therapeutic outcome of brain neoplasms. As techniques for gene therapy are advanced, manipulation of the BBB also may be important in the treatment of central nervous system genetic disorders.

Original languageEnglish (US)
Pages (from-to)1083-1100
Number of pages18
JournalNeurosurgery
Volume42
Issue number5
DOIs
StatePublished - 1998

Fingerprint

Blood-Brain Barrier
Therapeutics
Brain Neoplasms
Inborn Genetic Diseases
Central Nervous System Diseases
Brain
Bradykinin
Nervous System Diseases
Genetic Therapy
Neoplasms
History
Clinical Trials
Pharmacology

Keywords

  • Animal studies
  • Blood-Brain barrier
  • Blood-Brain barrier disruption
  • Brain tumor
  • Clinical studies
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Outwitting the blood-brain barrier for therapeutic purposes : Osmotic opening and other means. / Kroll, Robert A.; Neuwelt, Edward.

In: Neurosurgery, Vol. 42, No. 5, 1998, p. 1083-1100.

Research output: Contribution to journalArticle

@article{0cb946371c7840c4b8516d9dac19304d,
title = "Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means",
abstract = "OBJECTIVE: This article reviews historical aspects of the blood-brain barrier (BBB) and recent advances in mechanisms to deliver therapeutic agents across the BBB for the treatment of intracerebral tumors and other neurological diseases. METHODS: The development of the osmotic BBB disruption procedure as a clinically useful technique is described. Osmotic BBB disruption is contrasted with alternative methods for opening or bypassing the BBB, including pharmacological modification of the BBB with bradykinin and direct intracerebral infusion. RESULTS: Laboratory studies have played a fundamental role in advancing our understanding of the BBB and delivery of agents to brain. Preclinical animal studies will continue to serve an integral function in our efforts to improve the diagnosis and treatment of a number of neurological disorders. Techniques involving the modification of the BBB and/or blood-tumor barrier to increase delivery of therapeutic agents have been advanced to clinical trials in patients with brain tumors with very favorable results. CONCLUSION: Improving delivery of agents to the brain will play a major role in the therapeutic outcome of brain neoplasms. As techniques for gene therapy are advanced, manipulation of the BBB also may be important in the treatment of central nervous system genetic disorders.",
keywords = "Animal studies, Blood-Brain barrier, Blood-Brain barrier disruption, Brain tumor, Clinical studies, Treatment",
author = "Kroll, {Robert A.} and Edward Neuwelt",
year = "1998",
doi = "10.1097/00006123-199805000-00082",
language = "English (US)",
volume = "42",
pages = "1083--1100",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Outwitting the blood-brain barrier for therapeutic purposes

T2 - Osmotic opening and other means

AU - Kroll, Robert A.

AU - Neuwelt, Edward

PY - 1998

Y1 - 1998

N2 - OBJECTIVE: This article reviews historical aspects of the blood-brain barrier (BBB) and recent advances in mechanisms to deliver therapeutic agents across the BBB for the treatment of intracerebral tumors and other neurological diseases. METHODS: The development of the osmotic BBB disruption procedure as a clinically useful technique is described. Osmotic BBB disruption is contrasted with alternative methods for opening or bypassing the BBB, including pharmacological modification of the BBB with bradykinin and direct intracerebral infusion. RESULTS: Laboratory studies have played a fundamental role in advancing our understanding of the BBB and delivery of agents to brain. Preclinical animal studies will continue to serve an integral function in our efforts to improve the diagnosis and treatment of a number of neurological disorders. Techniques involving the modification of the BBB and/or blood-tumor barrier to increase delivery of therapeutic agents have been advanced to clinical trials in patients with brain tumors with very favorable results. CONCLUSION: Improving delivery of agents to the brain will play a major role in the therapeutic outcome of brain neoplasms. As techniques for gene therapy are advanced, manipulation of the BBB also may be important in the treatment of central nervous system genetic disorders.

AB - OBJECTIVE: This article reviews historical aspects of the blood-brain barrier (BBB) and recent advances in mechanisms to deliver therapeutic agents across the BBB for the treatment of intracerebral tumors and other neurological diseases. METHODS: The development of the osmotic BBB disruption procedure as a clinically useful technique is described. Osmotic BBB disruption is contrasted with alternative methods for opening or bypassing the BBB, including pharmacological modification of the BBB with bradykinin and direct intracerebral infusion. RESULTS: Laboratory studies have played a fundamental role in advancing our understanding of the BBB and delivery of agents to brain. Preclinical animal studies will continue to serve an integral function in our efforts to improve the diagnosis and treatment of a number of neurological disorders. Techniques involving the modification of the BBB and/or blood-tumor barrier to increase delivery of therapeutic agents have been advanced to clinical trials in patients with brain tumors with very favorable results. CONCLUSION: Improving delivery of agents to the brain will play a major role in the therapeutic outcome of brain neoplasms. As techniques for gene therapy are advanced, manipulation of the BBB also may be important in the treatment of central nervous system genetic disorders.

KW - Animal studies

KW - Blood-Brain barrier

KW - Blood-Brain barrier disruption

KW - Brain tumor

KW - Clinical studies

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0031965788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031965788&partnerID=8YFLogxK

U2 - 10.1097/00006123-199805000-00082

DO - 10.1097/00006123-199805000-00082

M3 - Article

C2 - 9588554

AN - SCOPUS:0031965788

VL - 42

SP - 1083

EP - 1100

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 5

ER -